Contract manufacturing organisation Celonic has signed an agreement with Curevac to produce 100 million doses of the latter’s mRNA-based Covid-19 vaccine candidate, CVnCoV. More than 50 million doses are expected to be produced by the end of 2021 at Celonic’s facility in Heidelberg, Germany. CureVac confirmed its expected output capacity of its European manufacturing network to be 300 million doses in 2021.

Pharmaceutical company Tetra Biopharma has received Health Canada approval for clinical trial application for evaluating ARDS-003 in Covid-19 patients. ARDS-003 is derived from cannabinoids, and is designed to treat severe inflammatory responses that can be fatal after Covid-19 infection. The study will assess the safety, efficacy, tolerability, and pharmacokinetics of ARDS-003 in hospitalised patients with pneumonia who are at a risk of developing acute respiratory distress syndrome.

Tiziana Life Sciences plans to continue the development of its anti-CD3 human monoclonal antibody, Foramulab, against Covid-19. Early-stage data of the nasally-administered drug’s performance in patients with mild to moderate Covid-19 showed reductions in pulmonary and systemic inflammation, with good tolerability. The company is now planning a randomised, placebo-controlled Phase II trial in Brazil for patients hospitalised with moderate to severe Covid-19.